Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
SMMT · Why this verdict
Why Summit Therapeutics (SMMT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analyst consensus implies 102% upside from the current price of $14.13 to a target of approximately $28.54, reflecting institutional belief that the ivonescimab clinical program will succeed, which provides significant asymmetric return potential if the trial data is positive. Sentiment breakdown | Stock price reaches at least $22, capturing more than half of the analyst-implied upside, within 12 months upon positive clinical news. | →Stable |
| CounterAnalyst targets in clinical-stage biotechnology are forward-looking success-scenario valuations; if the trial fails, targets are withdrawn and the stock may trade near cash value of less than $3 per share. | ||
The entire valuation of Summit Therapeutics rests on ivonescimab, a bispecific antibody licensed from Akeso for development outside Greater China, concentrating all clinical, regulatory, and commercial risk into a single molecule and a single licensor relationship. Bear case | A positive pivotal trial readout for ivonescimab is reported within 12 months, demonstrating statistically significant clinical benefit that supports a regulatory filing. | →Stable |
| CounterSingle-asset biotechnology companies can reach significant market capitalizations before their lead drug receives approval; if a trial reads out negatively, the stock would likely fall more than 60% within days, and there is no secondary pipeline to provide any recovery floor. | ||
Short interest of 27% of float is one of the highest in the healthcare sector and is flagged as justified by the data, indicating that a significant proportion of informed institutional investors are betting against the company's clinical success or commercial viability. Risk breakdown | Short interest falls below 15% within 12 months as clinical de-risking events cause bears to cover and reduce their positions. | →Stable |
| CounterIn clinical-stage biotechnology, high short interest often represents a short squeeze setup rather than an informational signal; if pivotal trial data reads out positively, covering of 27% short float could amplify price gains by 40 to 60% beyond the fundamental move. | ||
After 3 consecutive large earnings misses in 2025, Summit beat estimates by 14.25% in the most recent quarter with a loss of $0.18 versus an estimate of $0.21, suggesting the cash burn rate may be stabilizing as the clinical program advances toward a readout. Earnings | Cash burn per quarter remains below $0.25 per share for at least 3 consecutive quarters, indicating operational spending discipline is being maintained. | →Stable |
| CounterA single beat after 3 misses is insufficient to establish a trend; the company's burn rate is entirely dictated by its clinical trial timeline, and acceleration into a pivotal readout phase often increases spending significantly. | ||
Analyst consensus implies 102% upside from the current price of $14.13 to a target of approximately $28.54, reflecting institutional belief that the ivonescimab clinical program will succeed, which provides significant asymmetric return potential if the trial data is positive.
→StableSentiment breakdown
- Expectation
- Stock price reaches at least $22, capturing more than half of the analyst-implied upside, within 12 months upon positive clinical news.
CounterAnalyst targets in clinical-stage biotechnology are forward-looking success-scenario valuations; if the trial fails, targets are withdrawn and the stock may trade near cash value of less than $3 per share.
The entire valuation of Summit Therapeutics rests on ivonescimab, a bispecific antibody licensed from Akeso for development outside Greater China, concentrating all clinical, regulatory, and commercial risk into a single molecule and a single licensor relationship.
→StableBear case
- Expectation
- A positive pivotal trial readout for ivonescimab is reported within 12 months, demonstrating statistically significant clinical benefit that supports a regulatory filing.
CounterSingle-asset biotechnology companies can reach significant market capitalizations before their lead drug receives approval; if a trial reads out negatively, the stock would likely fall more than 60% within days, and there is no secondary pipeline to provide any recovery floor.
Short interest of 27% of float is one of the highest in the healthcare sector and is flagged as justified by the data, indicating that a significant proportion of informed institutional investors are betting against the company's clinical success or commercial viability.
→StableRisk breakdown
- Expectation
- Short interest falls below 15% within 12 months as clinical de-risking events cause bears to cover and reduce their positions.
CounterIn clinical-stage biotechnology, high short interest often represents a short squeeze setup rather than an informational signal; if pivotal trial data reads out positively, covering of 27% short float could amplify price gains by 40 to 60% beyond the fundamental move.
After 3 consecutive large earnings misses in 2025, Summit beat estimates by 14.25% in the most recent quarter with a loss of $0.18 versus an estimate of $0.21, suggesting the cash burn rate may be stabilizing as the clinical program advances toward a readout.
→StableEarnings
- Expectation
- Cash burn per quarter remains below $0.25 per share for at least 3 consecutive quarters, indicating operational spending discipline is being maintained.
CounterA single beat after 3 misses is insufficient to establish a trend; the company's burn rate is entirely dictated by its clinical trial timeline, and acceleration into a pivotal readout phase often increases spending significantly.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Summit Therapeutics has a single clinical asset, ivonescimab, licensed exclusively from Akeso, with analysts projecting 102% upside and a risk-reward ratio of more than 10 to 1, but the quality score of 1.8, 27% short interest, and 3 consecutive earnings misses before the most recent quarter reflect the binary nature of the investment.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.8/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.6 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 0.7 |
- ▸Overbought bear rally (RSI 74)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.4%/30d — confirmed downtrend
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.5 |
| Analyst rating | 7.2 |
| Price target | 9.9 |
- ▸Analyst upside: 79%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 5.0 |
- ▸Heavy insider buying — $103,616,650 (0.866% of mkt cap)
Peer rank
3.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
0.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.0 |
| 52w position | 0.3 |
Risk (lower is worse)
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.8 |
| days to cover | 4.8 |
| volatility | 1.6 |
| put call | 8.4 |
| implied vol | 0.0 |
| debt equity | 1.3 |
- ▸High short interest justified: 27%
- ▸High IV: 99%
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 2.5 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:5.5>=4.5
- ASYMMETRY:3.7>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:36d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- MOMENTUM:5.5<5.5 (soft — BUY_NOW allowed but watch)
- DEATH_CROSS:momentum=5.5>=5.0 recovering
Reward-to-Risk
3.74
Upside
+56.1%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 74
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -49% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.4, and Insider at 7.3; the weakest are Technical at 0.1, Quality at 1.8, and Risk (lower is worse) at 2.8. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 3.74 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Ivonescimab Single Asset Binary
Trip ifThe share price drops below $7, more than 50% below the current $14.13, following a pivotal-trial setback or clinical hold on the lead asset.
- P2Analyst Consensus 100pct Upside
Trip ifAnalyst consensus price target falls below $18, reducing implied upside to less than 27% from the current price of $14.13.
- P3High Short Interest Informed Bears
Trip ifShort interest rises above 35% of float outstanding.
- P4Earnings Burn Rate Stabilizing
Trip ifQuarterly cash burn per share exceeds $0.40, more than double the most recent reported $0.18 per share loss.